August 21, 2014 7:16 AM ET

Biotechnology

Company Overview of Mimetogen Pharmaceuticals Inc.

Company Overview

Mimetogen Pharmaceuticals Inc., a biotechnology company, engages in designing and developing small molecule drugs to treat dry eye, glaucoma, age-related macular degeneration, keratoconus, and retinitis pigmentosa. The company’s products mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. It provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded in 2...

1000 de La Gauchetière Street West

Suite 900

Montreal, QC H3B 5H4

Canada

Founded in 2004

Phone:

514-667-5869

Fax:

240-306-0500

Key Executives for Mimetogen Pharmaceuticals Inc.

Chief Executive Officer
Chief Financial Officer and Vice President of Finance
Chief Medical Officer
Senior Director - Drug Discovery
Senior Scientist - Medicinal Chemistry
Compensation as of Fiscal Year 2014.

Mimetogen Pharmaceuticals Inc. Key Developments

Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome

Mimetogen Pharmaceuticals Inc. announced that the initial patients have been enrolled in the company's first pivotal Phase 3 clinical study of MIM-D3 ophthalmic solution for the treatment of dry eye syndrome. MIM-D3 is the first in a class of molecules called TrkA agonists. MIM-D3 stimulates the production of mucin, which plays a critical role in the protection and overall health of the ocular surface. Mucins are essential for lubrication; the removal of allergen, pathogens, and debris; and corneal epithelial healing to reduce ocular surface damage. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies, including the potential to improve neural function, which may improve corneal sensitivity and integrity. The pivotal trial will further evaluate the safety and efficacy of MIM-D3 in the treatment of dry eye syndrome. Approximately 400 patients will be randomized to receive 1% MIM-D3 ophthalmic solution or placebo twice daily over an 8 week period. The primary endpoints of the study are corneal fluorescein staining score in the CAE(SM) and ocular dryness. The safety and comfort of MIM-D3 compared to placebo will also be evaluated.

Mimetogen Pharmaceuticals Inc. Presents at BIO-Europe 2012, Nov-12-2012

Mimetogen Pharmaceuticals Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.

Similar Private Companies By Industry

Company Name Region
Welichem Biotech Inc. Americas
BioAxone Therapeutic, Inc. Americas
Feldan Bio Inc. Americas
CanPro Ingredients Ltd. Americas
REPLICor Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mimetogen Pharmaceuticals Inc., please visit www.mimetogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.